Methods for enhancing the specific uptake of botulinum neurotoxins into cells

Patent metadata

Field	Value
Publication number	US-10725025-B2
Application number	US-201615554338-A
Country	US
Kind code	B2
Filing date	Mar 3, 2016
Priority date	Mar 4, 2015
Publication date	Jul 28, 2020
Grant date	Jul 28, 2020

Abstract

The present invention provides a method for enhancing the specific uptake of a neurotoxin polypeptide into cells, the method comprising: incubating cells susceptible to neurotoxin intoxication with a neurotoxin polypeptide for a time and under conditions which allow for the neurotoxin polypeptide to exert its biological activity, the incubation comprising at least one of the following steps: (i) K + -mediated depolarization of the cells, (ii) a reduced neurotoxin polypeptide exposition time and/or (iii) agitation of the cells during neurotoxin polypeptide exposition, thereby enhancing the specific uptake of the neurotoxin polypeptide into said cells. In addition, the invention pertains to a method for directly determining the biological activity of a neurotoxin polypeptide in cells, comprising: a) incubating cells susceptible to neurotoxin intoxication with a neurotoxin polypeptide for a time and under conditions which allow for the neurotoxin polypeptide to exert its biological activity, the incubation comprising at least one of the following steps: (i) K + -mediated depolarization of the cells, (ii) a reduced neurotoxin polypeptide exposition time and/or (iii) agitation of the cells during neurotoxin polypeptide exposition; b) fixing the cells and, optionally, permeabilizing the cells with a detergent; c) contacting the cells with at least a first capture antibody specifically binding to the non-cleaved and neurotoxin-cleaved substrate and with at least a second capture antibody specifically binding to the cleavage site of the neurotoxin-cleaved substrate, under conditions which allow for binding of said capture antibodies to said substrates; d) contacting the cells with at least a first detection antibody specifically binding to the first capture antibody, under conditions which allow for binding of said first detection antibody to said first capture antibody, thus forming first detection complexes and with at least a second detection antibody specifically binding to the second capture antibody, under conditions which allow for binding of said second detection antibody to said second capture antibody, thus forming second detection complexes; e) determining the amount of the first and second detection complexes of step d); and f) calculating the amount of substrate cleaved by said neurotoxin polypeptide in said cells by means of the second detection complexes, thereby determining the biological activity of said neurotoxin polypeptide in said cells.

First claim

The invention claimed is:

1. A method for enhancing the specific uptake of a neurotoxin polypeptide into cells, the method comprising:
incubating cells susceptible to neurotoxin intoxication with a neurotoxin polypeptide for a time and under conditions which allow for the neurotoxin polypeptide to exert its biological activity, the incubation comprising at least two of the following steps: (i) K + -mediated depolarization of the cells, (ii) a reduced neurotoxin polypeptide exposition time and/or (iii) agitation of the cells during neurotoxin polypeptide exposition, thereby enhancing the specific uptake of the neurotoxin polypeptide into said cells.

2. The method of claim 1 , followed by determining the biological activity of the neurotoxin polypeptide in the cells.

3. A method for directly determining the biological activity of a neurotoxin polypeptide in cells, comprising:
a) incubating cells susceptible to neurotoxin intoxication with a neurotoxin polypeptide for a time and under conditions which allow for the neurotoxin polypeptide to exert its biological activity, the incubation comprising at least two of the following steps: (i) K + -mediated depolarization of the cells, (ii) a reduced neurotoxin polypeptide exposition time and/or (iii) agitation of the cells during neurotoxin polypeptide exposition;
b) fixing the cells and, optionally, permeabilizing the cells with a detergent;
c) contacting the cells with at least a first capture antibody specifically binding to a non-cleaved and neurotoxin-cleaved substrate and with at least a second capture antibody specifically binding to the cleavage site of the neurotoxin-cleaved substrate, under conditions which allow for binding of said capture antibodies to said substrates;
d) contacting the cells with at least a first detection antibody specifically binding to the first capture antibody, under conditions which allow for binding of said first detection antibody to said first capture antibody, thus forming first detection complexes and with at least a second detection antibody specifically binding to the second capture antibody, under conditions which allow for binding of said second detection antibody to said second capture antibody, thus forming second detection complexes;
e) determining the amount of the first and second detection complexes of step d); and
f) calculating the amount of substrate cleaved by said neurotoxin polypeptide in said cells by means of the second detection complexes, thereby determining the biological activity of said neurotoxin polypeptide in said cells.

4. The method of claim 3 , wherein the K + -mediated depolarization of the cells is carried out at an additional K + concentration of about 20 mM to about 55 mM, for at least 2 hours.

5. The method of claim 3 , wherein the K + -mediated depolarization of the cells and/or the neurotoxin polypeptide exposition is carried out in the presence of GT1b.

6. The method of claim 5 , wherein GT1b is used in a concentration between 15 and 50 μM.

7. The method of claim 3 , wherein the reduced neurotoxin polypeptide exposition time is exposition of the cells to the neurotoxin polypeptide for at least 24 hours and less than 96 hours.

8. The method of claim 3 , wherein agitation of the cells during neurotoxin polypeptide exposition is carried out with a magnetic stirrer, rotating spinner flasks or shaking of the cells by a shaker.

9. The method of claim 3 , wherein the K + -mediated depolarization of the cells is carried out at an additional K + concentration of about 20 mM to about 55 mM, for at least 2 hours in the presence of 20 μM GT1b and neurotoxin polypeptide, followed by neurotoxin polypeptide exposition for additional 70 hours under agitation.

10. The method of claim 3 , wherein an incubation time without neurotoxin polypeptide precedes the neurotoxin polypeptide exposition.

11. The method of claim 10 , wherein the incubation time without neurotoxin polypeptide is between 16 and 48 hours.

12. The method of claim 3 , wherein the method is a fluorescence method.

13. The method of claim 3 , wherein the neurotoxin polypeptide is BoNT/A, BoNT/B, BoNT/C1, BoNT/D, BoNT/E, BoNT/F, BoNT/G, BoNT/H, or subtypes thereof.

14. The method of claim 3 , wherein the substrate is VAMP/Synaptobrevin, SNAP-25 or Syntaxin.

15. The method of claim 3 , wherein the cells are neuronal cells or neuronal differentiated cells selected from the group consisting of: primary neuronal cells, tumor cells which are capable of differentiating to neuronal cells, P19 cells or induced pluripotent stem cell (IPS)-derived neurons.

16. The method of claim 1 , wherein the K + -mediated depolarization of the cells is carried out at an additional K + concentration of about 20 mM to about 55 mM, for at least 2 hours.

17. The method of claim 1 , wherein the K + -mediated depolarization of the cells and/or the neurotoxin polypeptide exposition is carried out in the presence of GT1b.

18. The method of claim 1 , wherein the reduced neurotoxin polypeptide exposition time is exposition of the cells to the neurotoxin polypeptide for at least 24 hours and less than 96 hours.

19. The method of claim 1 , wherein agitation of the cells during neurotoxin polypeptide exposition is carried out with a magnetic stirrer, rotating spinner flasks or shaking of the cells by a shaker.

20. The method of claim 1 , wherein the K + -mediated depolarization of the cells is carried out at an additional K + concentration of at least about 20 mM to about 55 mM, for at least-2 hours in the presence of 20 μM GT1b and neurotoxin polypeptide, followed by neurotoxin polypeptide exposition for additional 70 hours under agitation.

21. The method of claim 1 , wherein an incubation time without neurotoxin polypeptide precedes the neurotoxin polypeptide exposition.

22. The method of claim 1 , wherein the neurotoxin polypeptide is BoNT/A, BoNT/B, BoNT/C1, BoNT/D, BoNT/E, BoNT/F, BoNT/G, BoNT/H, or subtypes thereof.

23. The method of claim 1 , wherein the cells are neuronal cells or neuronal differentiated cells selected from the group consisting of: primary neuronal cells, tumor cells which are capable of differentiating to neuronal cells, P19 cells or induced pluripotent stem cell (IPS)-derived neurons.

24. The method of claim 15 , wherein the tumor cells which are capable of differentiating to neuronal cells are neuroblastoma cells.

25. The method of claim 23 , wherein the tumor cells which are capable of differentiating to neuronal cells are neuroblastoma cells.

Assignees

• Merz Pharma Gmbh & Co Kgaa

Inventors

• Jatzke Claudia
• Eisele Karl-Heinz
• Mander Gerd
• Fink Klaus

Classifications

• G01N33/53 Primary

  Immunoassay; Biospecific binding assay; Materials therefor · CPC title

• G01N2333/33

  from Clostridium (G) · CPC title

• G01N33/5058 Primary

  Neurological cells · CPC title

• C12N5/0619

  Neurons · CPC title

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title